Interferon Beta-1a
Brand Names: Avonex, Rebif Rebidose, Rebif, Avonex Pen
Methodology & AI Transparency ⓘ
Interferon Beta-1a Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage avonex: is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- 2 Real-world patient consensus: Real-world cohort score of 78% across 14 de-identified Interferon Beta-1a entries.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $185.00 cash mean against $453.25 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Interferon Beta-1a): myalgia (3.4%), dizziness (6.4%), headache (5.5%).
Ask our AI Specialists anything about Interferon Beta-1a
Interferon Beta-1a Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage avonex: is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. AVONEX is for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
12.1 Mechanism of Action The mechanism of action by which AVONEX exerts its effects in patients with multiple sclerosis is unknown. In clinical regimens (Kit, 30 ug/.5mL Injection, Solution), Interferon Beta-1a executes interferon beta target modulation documented under federal RxCUI 727813 and DailyMed 2025-11-19 labeling.
Pharmacokinetic profiling of Interferon Beta-1a demonstrates an elimination half-life of Mean elimination half-life of 7 to 16 hours across adult Interferon Beta-1a dosing with Oral fraction absorbed ranges from 70% to 82% (Interferon Beta-1a Kit) systemic bioavailability; clearance proceeds via dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of interferon beta-1a, reaching clinical onset within oral tmax achieved within 2 to 3 hours following interferon beta-1a ingestion.
Titration schedules for Interferon Beta-1a (Kit → 30 ug/.5mL Injection, Solution → 22 ug/.5mL Injection, Solution → 44 ug/.5mL Injection, Solution) require excluding 4 contraindications avonex is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation .; the formerly available lyophilized vial formulation of avonex is contraindicated in patients with a history of hypersensitivity to albumin (human).; real-world patient logs highlight dizziness (6.4% of reports), headache (5.5% of reports), fatigue (5.4% of reports) alongside a 78.00% Worth-It consensus.
Verify medication reconciliation lists so Interferon Beta-1a is not inadvertently duplicated with another interferon beta.
Unstandardized herbal extracts may interact pharmacodynamically with Interferon Beta-1a maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS AVONEX is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation .
- The formerly available lyophilized vial formulation of AVONEX is contraindicated in patients with a history of hypersensitivity to albumin (human).
Logged Side-Effect Incidence (14 Reports)
Interferon Beta-1a Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Interferon Beta-1a)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for: What a 1,057-Participant Study Found Clinical and radiological outcomes generally favored DRF versus IFN. Journal of comparative effectiveness research • 2024-10-15 • Phase III Randomized Trial | N = 1,057 | 96/100 | PMID 39158844 ↗ |
| New Insights on Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of: What a 1,156-Participant Study Found After accounting for therapeutic lag and differences between ASCEND and SPECTRIMS trials, natalizumab, compared. Journal of neurology, neurosurgery, and psychiatry • 2025-09-12 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 40050011 ↗ |
| Can This Approach Help? Inside the Latest Research on Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter Findings reported here add new insights into the complex mechanisms of pseudo-atrophy and its relation to the compartmentalized inflammation occurring in the GM of MS patients. Annals of clinical and translational neurology • 2021-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33534940 ↗ |
| New Insights on Type I interferon blockade with anifrolumab in patients with systemic lupus: What a 244-Participant Study Found Compared with placebo, anifrolumab modulated >2000 genes by week 24, with overlapping results at week 52, and 41 proteins by week 52. Annals of the rheumatic diseases • 2024-07-15 • Phase III Randomized Trial | N = 244 | 88/100 | PMID 38569851 ↗ |
| Can This Approach Help? Inside the Latest Research on Multiple sclerosis clinical decision support system based on projection to The pioneer use of PORs for each individual patient enables personalized analytics sustaining the dialog between neurologists, patients and caregivers with quantified evidence. Annals of clinical and translational neurology • 2022-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36412095 ↗ |
Interferon Beta-1a Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $8406.9391/unit (~$252208.17/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Interferon Beta-1a Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Interferon Beta-1a RxNorm Concept ID | 727813 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $8406.9391 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Interferon Beta-1a Patient Community, Cohort Filters & Dosage Logs
Deterministic Interferon Beta-1a reference combining NIH RxNorm (727813), Medicaid NADAC ($8406.9391/unit), and anonymous cohort outcomes (78% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Interferon Beta-1a community threads and patient logs by age, biological sex, dosage, and treatment duration.